SNSE — Sensei Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00
- $16.78m
- -$39.86m
- 35
- 53
- 49
- 42
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 12.5 | 19.4 | 36.9 | 50.2 | 37.1 |
Operating Profit | -12.5 | -19.4 | -36.9 | -50.2 | -37.1 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -16.7 | -20.1 | -36.8 | -48.6 | -34.1 |
Net Income After Taxes | -16.7 | -20.1 | -36.8 | -48.6 | -34.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -16.7 | -20.1 | -36.8 | -48.6 | -34.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.5 | -20.2 | -36.8 | -48.6 | -34.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.693 | -0.66 | -1.35 | -1.58 | -1.2 |
Dividends per Share |